Neogen (NASDAQ:NEOG) Raised to Strong-Buy at Wall Street Zen

Neogen (NASDAQ:NEOG – Get Free Report) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also weighed in on NEOG. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neogen in a research note on Wednesday, November 4th. Piper Sandler raised shares of Neogen from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $14.00 in a report on Wednesday, August 26th. Finally, Guggenheim restated a “buy” rating and issued a $14.00 target price (up from $12.00) on shares of Neogen in a research note on Wednesday, September 30th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.67.

Get Our Latest Stock Report on Neogen

Neogen Price Performance

NEOG stock opened at $11.23 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.90 and a quick ratio of 2.92. Neogen has a 1-year low of $5.37 and a 1-year high of $14.26. The firm has a fifty day moving average price of $12.24 and a two-hundred day moving average price of $10.52. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -44.92, a PEG ratio of 4.01 and a beta of 1.86.

Neogen (NASDAQ:NEOG – Get Free Report) last posted its quarterly earnings results on Tuesday, October 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. Neogen had a negative net margin of 6.35% and a positive return on equity of 3.29%. The company had revenue of $222.80 million for the quarter, compared to the consensus estimate of $208.18 million. During the same period last year, the firm posted $0.04 EPS. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. Research analysts predict that Neogen will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Neogen

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Neogen during the second quarter worth approximately $300,545,000. Dimensional Fund Advisors LP grew its holdings in Neogen by 23.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,132,021 shares of the company’s stock worth $84,831,000 after buying an additional 1,733,767 shares in the last quarter. Bamco Inc. NY acquired a new stake in Neogen in the 2nd quarter valued at approximately $45,094,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in Neogen by 1.4% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,537,645 shares of the company’s stock valued at $45,282,000 after acquiring an additional 49,399 shares during the period. Finally, Cibc World Market Inc. acquired a new stake in Neogen in the 2nd quarter valued at approximately $31,469,000. 96.73% of the stock is currently owned by institutional investors.

Neogen Company Profile

(Get Free Report)

Neogen Corporation develops and markets products and services focused on food and animal safety. Its offerings help food producers, processors, laboratories and livestock producers detect risks, support animal health and meet safety and quality requirements. Neogen’s food safety products include tests for foodborne pathogens, allergens, toxins and sanitation indicators, as well as related laboratory supplies and services. Its animal safety offerings include veterinary instruments, animal health products, biosecurity solutions and genetic testing services for livestock.

See Also

Analyst Recommendations for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.